Companies/US/DHR

DANAHER CORPORATION

Income flow

Annual
DHR 10-K Income StatementPeriod 2025-12-31Source 10-K
Diagnostics Segment$10BLife Sciences Segment$7BBiotechnology Segment$7BRevenue$25B+3% Y/YGross profit$15B+2% Y/YCost of revenue$10BOperating profit$5B-4% Y/YOperating expenses$10BNet profit$4B-7% Y/YTax$633MSG&A$8BR&D & other$2B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$24.6B
  • Diagnostics Segment$9.9B40.5%
  • Life Sciences Segment$7.3B29.9%
  • Biotechnology Segment$7.3B29.7%
By geography
By geography$49.1B
  • All Other Countries$12.0B24.3%
  • North America$10.4B21.1%
  • United States$10.0B20.3%
  • High Growth Markets$7.0B14.3%
  • Western Europe$5.9B12.1%
  • CN$2.6B5.3%
  • Other Developed Markets$1.3B2.5%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.72%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.0.43%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).1.44PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.25.7%Shares outTotal shares currently outstanding (issued and not retired).703.0MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).625.9M
Upcoming dividend
Ex-dividend
2026-09-30
Next pay
2026-10-30
Last cash
0.4 · 2026-09-30
Stock splits
  1. 1128:10002023-10-02

Valuation

Trailing PE 45.1 (2025-12-31)PE trend

Fiscal PE5

PeriodEPSClosePE
2025-12-315.05227.5645.1
2024-12-315.29226.7642.9
2023-12-316.38227.5535.7
2022-12-319.66204.2621.1
2021-12-318.61252.2329.3

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.